ClinicalTrials.gg
RecruitingNCT05901974Updated Dec 16, 2025

Venetoclax Combined With Azactidine in the Treatment of ALAL

A Phase 2 interventional study of Venetoclax and azactidine in Acute Leukemia of Ambiguous Lineage, sponsored by Sheng-Li Xue, MD. Recruiting at 1 site in China. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Sheng-Li Xue, MD · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing venetoclax in Leukemia, Biphenotypic, Acute — 6 open to participants now, 10 under way, none of them phase 3. venetoclax · Leukemia, Biphenotypic, Acute.

Planned enrollment
10th of 13
23 · median 37
Started
2023
the only one that year
Phase 2
9 of 13
5 open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Sheng-Li Xue, MD

Among the 13 studies testing venetoclax in Leukemia, Biphenotypic, Acute, this one is the 10th largest by planned enrollment, is the only one that started in 2023, is one of 9 in phase 2, and was the 10th registered.

Leukemia, Biphenotypic, Acute

246 studies on the registry are indexed under Leukemia, Biphenotypic, Acute; 53 are open to participants now.

Browse Leukemia, Biphenotypic, Acute studies →

Open to participants now

6 of the 13 studies testing venetoclax in Leukemia, Biphenotypic, Acute are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Leukemia, Biphenotypic, Acute studies recruiting now, 21 (45%) set no upper age limit and 21 (45%) stop at 75 or younger; 29 take children under 18; 3 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing venetoclax in Leukemia, Biphenotypic, Acute, or all of them as a file.
02

Study summary

The prognosis of acute leukaemias of ambiguous lineage is poor. The effect of chemotherapy regimen and hematopoietic stem cell transplantation are still unclear. Therefore, we will explore new therapy to improve the remission rate of acute leukaemias of ambiguous lineage. Venetoclax can significantly improve the remission rate and prolong PFS and OS. At present, venetoclax combined with azacitidine or decitabine has become the preferred treatment regimen for elderly AML patients. It also shows a high response rate in relapsed/refractory AML or MDS patients. There are few clinical studies on the treatment of ALAL. The purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine in the treatment of newly diagnosed ALAL patients.

03

Conditions studied

  • Acute Leukemia of Ambiguous Lineage
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥ 15 years.
  2. Patients diagnosed with ALAL according to 5th edition of WHO Acute Leukaemias of Ambiguous Lineage diagnosis standard.
  3. New diagnosed patients.
  4. performance status score less than 3.
  5. Expected survival time ≥3 months.
  6. Patients without serious heart, lung, liver, or kidney disease.
  7. Ability to understand and voluntarily provide .

Exclusion criteria

Exclusion Criteria:

  1. Patients who are allergic to the study drug or drugs with similar chemical structures.
  2. Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of .
  3. Active infection.
  4. Active bleeding.
  5. Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment.
  6. Patients with mental disorders or other conditions whereby cannot be obtained and where the requirements of the study treatment and procedures cannot be met.
  7. Liver function abnormalities (total > 1.5 times the , /AST > 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST > 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine > 1.5 times the upper limit of the normal value).
  8. Patients with a history of prolongation (male > 450 ms; female > 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment.
  9. Surgery on the main organs within the past six weeks.
  10. Drug abuse or long-term alcohol abuse that would affect the evaluation results.
  11. Patients who have received organ transplants (excepting bone marrow transplantation).
  12. Patients not suitable for the study according to the investigator's assessment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    Venetoclax Combined With azactidine in the Treatment of Acute Leukaemias of Ambiguous Lineage

    Venetoclax combined with azacitidine regimen. Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .

    Drug: Venetoclax · Drug: azactidine

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    The overall response (complete remission, complete remission with incomplete blood count recovery) rate achieved after one or two courses (28 days) induction therapy by venetoclax combined azacitidine regimen.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Complete Remission Rate (CRR)

    The complete remission rate achieved after one or two courses (28 days) induction therapy by venetoclax combined azacitidine regimen.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

Secondary outcomes

  1. Overall survival (OS)

    It is measured from the date of entry into this trial to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive.

    Time frame: 1 year

  2. Progression-Free Survival (PFS)

    It is measured from the date of entry into this trial to the date of progression or death.

    Time frame: 1 year

  3. Adverse events in hematological system

    Record of adverse events in hematological system during and after designed venetoclax combined azacitidine regimen induction.

    Time frame: 1 year

  4. Adverse events in other organs or systems

    Record of adverse events in other organs or systems during and after designed venetoclax combined azacitidine regimen induction.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Mar 2026, 32 months after the start.

Of 42 phase 2 interventional studies under Leukemia, Biphenotypic, Acute, half reached primary completion within 102 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 153. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2023
First posted
Jun 13, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Mar 1, 2026
CompletionEst.
Mar 1, 2026
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05901974
Lead sponsor
Sheng-Li Xue, MD
Collaborators
Jining Medical University, The Second People's Hospital of Huai'an, The First Affiliated Hospital of Bengbu Medical University, Affiliated Hospital of Nantong University, Suzhou Hospital of Traditional Chinese Medicine, Northern Jiangsu People's Hospital, First Affiliated Hospital of Pingdingshan University, Second Affiliated Hospital of Wannan Medical College, Canglang Hospital of Suzhou
Responsible party
Sheng-Li Xue, MD (Professor, The First Affiliated Hospital of Soochow University) — Sponsor-investigator
First posted
Jun 13, 2023
Start date
Jul 1, 2023
Primary completion
Mar 1, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Dec 16, 2025

Study contacts

Sheng-Li Xue, MD
Contact
slxue@suda.edu.cn
0086-0512-67781139

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Interleukin-2 · Azacitidine · Cyclophosphamide · Sirolimus

Start the discussion